Innoviva (INVA) Free Cash Flow Growth (3y) (2013 - 2026)
Innoviva (INVA) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 10.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.69% |
| Sep 30, 2025 | -9.84% |
| Jun 30, 2025 | -17.69% |
| Mar 31, 2025 | -20.86% |
| Sep 30, 2024 | -21.34% |
| Jun 30, 2024 | -19.76% |
| Mar 31, 2024 | -23.91% |
| Sep 30, 2023 | 12.99% |
| Jun 30, 2023 | -21.78% |
| Mar 31, 2023 | -29.58% |
| Sep 30, 2022 | 49.76% |
| Jun 30, 2022 | 11.83% |
| Mar 31, 2022 | 8.57% |
| Sep 30, 2021 | 64.06% |
| Jun 30, 2021 | 17.83% |
| Mar 31, 2021 | 19.00% |
| Dec 31, 2020 | 21.23% |
| Sep 30, 2020 | 19.68% |
| Jun 30, 2020 | 52.18% |
| Mar 31, 2020 | 38.32% |